LAPADULA GIUSEPPE

d’Arminio Monforte, A., Tavelli, A., Di Biagio, A., Sarmati, L., Marchetti, G., Bai, F., et al. (2024). Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY [10.1093/jac/dkae081]. Detail

Tusch, E., Ryom, L., Pelchen-Matthews, A., Mocroft, A., Elbirt, D., Oprea, C., et al. (2024). Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration. CLINICAL INFECTIOUS DISEASES [10.1093/cid/ciae228]. Detail

Lapadula, G., Mezzadri, L., Lo Cascio, G., Antolini, L., Malandrin, S., Ranzani, A., et al. (2024). Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study. INFECTION [10.1007/s15010-024-02250-9]. Detail

Calcagno, A., Coppola, N., Sarmati, L., Tadolini, M., Parrella, R., Matteelli, A., et al. (2024). Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine. INFECTION [10.1007/s15010-024-02183-3]. Detail

Esposito, S., Pagliano, P., De Simone, G., Guarino, A., Pan, A., Brambilla, P., et al. (2024). In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry. INFECTION [10.1007/s15010-024-02176-2]. Detail